DK1692181T3 - Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin - Google Patents
Leptinantagonist og fremgangsmåde til kvantitativ måling af leptinInfo
- Publication number
- DK1692181T3 DK1692181T3 DK04797956.2T DK04797956T DK1692181T3 DK 1692181 T3 DK1692181 T3 DK 1692181T3 DK 04797956 T DK04797956 T DK 04797956T DK 1692181 T3 DK1692181 T3 DK 1692181T3
- Authority
- DK
- Denmark
- Prior art keywords
- leptin
- quantitative measurement
- antagonist
- binding
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10353593A DE10353593A1 (de) | 2003-11-17 | 2003-11-17 | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
PCT/EP2004/013043 WO2005049655A1 (en) | 2003-11-17 | 2004-11-17 | Leptin antagonist and method for quantitative measurement of leptin |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1692181T3 true DK1692181T3 (da) | 2012-04-30 |
Family
ID=34609036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04797956.2T DK1692181T3 (da) | 2003-11-17 | 2004-11-17 | Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin |
Country Status (10)
Country | Link |
---|---|
US (1) | US7807154B2 (da) |
EP (1) | EP1692181B1 (da) |
JP (1) | JP2007536212A (da) |
CN (1) | CN1984930A (da) |
AT (1) | ATE540979T1 (da) |
AU (1) | AU2004291323A1 (da) |
DE (1) | DE10353593A1 (da) |
DK (1) | DK1692181T3 (da) |
ES (1) | ES2380341T3 (da) |
WO (1) | WO2005049655A1 (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7320868B2 (en) | 2004-03-19 | 2008-01-22 | Arieh Gertler | Leptin binding domain compositions and methods thereto |
US8969291B2 (en) * | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
US8227408B2 (en) * | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US8716220B2 (en) * | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
EP2326339A4 (en) * | 2008-05-21 | 2012-06-20 | Neurotez Inc | METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES |
WO2009149149A1 (en) * | 2008-06-04 | 2009-12-10 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
EP2663579B1 (en) | 2011-01-14 | 2017-04-26 | The Regents of the University of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
GB201113354D0 (en) | 2011-08-03 | 2011-09-21 | Univ Sheffield | Leptin receptor structure |
CN104459105B (zh) * | 2014-12-05 | 2016-03-09 | 重庆中元生物技术有限公司 | 一种检测lp的胶乳增强免疫比浊试剂盒及其制备方法 |
EP3261582B1 (en) * | 2015-02-26 | 2021-01-06 | Remodeless CV Ltd. | Methods and compositions relating to leptin antagonists |
US10105469B2 (en) * | 2015-02-26 | 2018-10-23 | Jacob Schneiderman | Composition-of-matter and method for treating cardiovascular disorders |
WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化psa組成物および方法 |
TWI752920B (zh) * | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
CA3030974A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
PT3509624T (pt) * | 2016-09-12 | 2023-08-28 | Amryt Pharmaceuticals Inc | Métodos de deteção de anticorpos neutralizantes anti-leptina |
EP3538554A1 (en) | 2016-11-08 | 2019-09-18 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
AU2018390811A1 (en) | 2017-12-18 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof |
EP3773713A1 (en) | 2018-04-06 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
CN110183530A (zh) * | 2019-06-21 | 2019-08-30 | 深圳市亚辉龙生物科技股份有限公司 | 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE29522109U1 (de) * | 1994-08-17 | 1999-12-02 | The Rockefeller University, New York, N.Y. | Modulatoren des Körpergewichts, korrespondierende Nukleinsäuren und Proteine |
AU4672199A (en) * | 1998-05-20 | 1999-12-06 | Yale University | Modulation of angiogenesis and wound healing |
CA2376933A1 (en) * | 1999-06-11 | 2000-12-21 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
WO2001096565A2 (en) * | 2000-06-16 | 2001-12-20 | Asterion Limited | Binding agents: chimeric ligand/receptor proteins |
-
2003
- 2003-11-17 DE DE10353593A patent/DE10353593A1/de not_active Withdrawn
-
2004
- 2004-11-17 JP JP2006540307A patent/JP2007536212A/ja active Pending
- 2004-11-17 CN CNA2004800400846A patent/CN1984930A/zh active Pending
- 2004-11-17 DK DK04797956.2T patent/DK1692181T3/da active
- 2004-11-17 AT AT04797956T patent/ATE540979T1/de active
- 2004-11-17 AU AU2004291323A patent/AU2004291323A1/en not_active Abandoned
- 2004-11-17 ES ES04797956T patent/ES2380341T3/es not_active Expired - Lifetime
- 2004-11-17 US US10/579,203 patent/US7807154B2/en not_active Expired - Fee Related
- 2004-11-17 EP EP04797956A patent/EP1692181B1/en not_active Expired - Lifetime
- 2004-11-17 WO PCT/EP2004/013043 patent/WO2005049655A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2004291323A1 (en) | 2005-06-02 |
WO2005049655A1 (en) | 2005-06-02 |
EP1692181A1 (en) | 2006-08-23 |
DE10353593A1 (de) | 2005-06-23 |
JP2007536212A (ja) | 2007-12-13 |
CN1984930A (zh) | 2007-06-20 |
US20080118503A1 (en) | 2008-05-22 |
US7807154B2 (en) | 2010-10-05 |
EP1692181B1 (en) | 2012-01-11 |
ATE540979T1 (de) | 2012-01-15 |
ES2380341T3 (es) | 2012-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1692181T3 (da) | Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin | |
NO20072721L (no) | Polypeptides that bind BR3 and uses thereof | |
ATE461449T1 (de) | Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben | |
NO20062886L (no) | IL-23 og dens reseptor, beslektede reagenser og fremgangsmater | |
EA201000245A1 (ru) | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf | |
BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
DK1287130T3 (da) | Cytokinreceptorunderenhedproteiner fra pattedyr, tilhörende reagenser og fremgangsmåder | |
EP1687283A4 (en) | PROCESS AND COMPOSITION FOR DETERMINING FK 506 | |
DE60130538D1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
BRPI0509419A (pt) | método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio | |
DE60331677D1 (de) | Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper | |
NO960924L (no) | Analysesett | |
EP1433792A8 (en) | Human receptor proteins, related reagents and methods | |
ATE477278T1 (de) | Monoklonaler antikörper gegen humanen frizzled-4- rezeptor | |
ATE418072T1 (de) | Verfahren zur diagnose von gebärmutterhalskrebs | |
EA200600376A1 (ru) | Антагонисты nogo-рецептора | |
DK1987057T3 (da) | Peptidaptamer til neutralisering af bindingen af platelet-antigen-specifikke antistoffer og diagnostiske og terapeutiske applikationer indeholdende den. | |
DE50212790D1 (de) | Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper | |
ATE383418T1 (de) | Verfahren und zusammensetzungen zur bestimmung glycierter proteine | |
DE60025022D1 (de) | Nachweis von hla-g | |
WO2006004958A3 (en) | Detection or measurement of antibodies to antigenic proteins in biological tissues or samples | |
DE602004001994D1 (de) | Verwendung des proteins masp als marker für kolorektale karzinome | |
ATE484748T1 (de) | Testverfahren zur bestimmung von analyten mittels analytanalogen | |
WO2005065711A3 (en) | Mammalian receptor proteins; related reagents and methods | |
BRPI0520902A2 (pt) | Anticorpo monoclonal ou fragmento de ligação a antigeno do mesmo que se liga a proteinas psca para disgnostico de cancer, metodo para produção dos mesmos, hib'ridoma, polinucleotideo, vetor, celula, composição, ensaio para detectar a presença de uma proteina'psca e metodo de detecção de uma proteina psca |